Akorn reported a GAAP net loss of $70.1 million, or $0.56 per diluted share, in the third quarter of 2018 compared with a GAAP net loss of $2.9 million, or $0.02 per diluted share, in 2017’s third quarter, according to a press release.
Net revenue decreased 18.2% from $202.4 million in 2017’s third quarter to $165.6 million this year. The decrease was attributed to a $39.6 million decline in organic revenue, predominately due to competition regarding ephedrine sulfate injection, lidocaine ointment, methylene blue injection and Nembutal (pentobarbital sodium injection), the (Read more...)
Uncategorized